Dr. King is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Ocean Ave.
Santa Monica, CA 90402Phone+1 310-310-3988- Is this information wrong?
Summary
- Dr. Christopher King is a Board Certified Radiation Oncologist in Santa Monica, CA. He received his MD from Boston University, PhD from Yale, Fellowship from Tufts, and has been in practice 27 years. He is experienced in Prostate cancer, GU cancers, and stereotactic body radiotherapy. He has more than 100 peer-reviewed publications.
Clinical Expertise
- Brachytherapy, Genitourinary cancer, Prostate cancer, Stereotactic radiosurgery, Radiotherapy, Radiation oncology, Stereotactic body radiotherapy
Education & Training
- Yale-New Haven Medical CenterResidency, Radiation Oncology, 1995 - 1998
- Steward Carney HospitalResidency, Internal Medicine, 1994 - 1995
- Boston University Medical CenterInternship, Transitional Year, 1993 - 1994
- Boston University School of MedicineClass of 1993
- Yale UniversityPhD, Astrophysics, 1987
Certifications & Licensure
- CA State Medical License 2000 - 2026
- MA State Medical License 1999 - 2000
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- SuperDoctors SuperDoctors, 2015-2020
- BestDoctors BestDoctors, 2003-2020
Publications & Presentations
PubMed
- 58 citationsIs the prostate α/β ratio of 1.5 from Brenner & Hall a modeling artifact?1Christopher R King, Charles S Mayo> ;International Journal of Radiation Oncology, Biology, Physics. 2000 May 1
- 11 citationsThe intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells.Nicholas G. Nickols, Ekambaram Ganapathy, Christine Nguyen, Nathanael Kane, Lin Lin, Silvia Diaz-Perez, Ramin Nazarian, Colleen Mathis, Care Felix, Vince Basehart, Naz...> ;Prostate Cancer and Prostatic Diseases. 2021 Mar 1
- 8 citationsDosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble ma...Xiaoying Pan, Rebecca Levin-Epstein, Jiahao Huang, Dan Ruan, Christopher R. King, Amar U. Kishan, Michael L. Steinberg, X. Sharon Qi> ;Radiotherapy and Oncology. 2020 Jul 1
- Join now to see all
Press Mentions
- Here’s the CDC’s New Advice for Protecting Yourself Against COVID-19August 11th, 2022
Professional Memberships
- Member
External Links
- Castle Connollyhttps://www.castleconnolly.com/top-doctors/christopher-r-king-radiation-oncology-16cc004955
- SuperDoctorshttps://www.superdoctors.com/california-los-angeles/doctor/Christopher-R-King/52c03d89-42a6-417f-9129-89b7a533c063.html
- UCLA profilehttps://cc.bingj.com/cache.aspx?q=cr+king+ucla+rad+onc&d=4928320517377500&mkt=en-US&setlang=en-US&w=Iu3dYrzZpsfBJCuKp5nfhwezQgzBaFSV
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: